Early ADME research helps drug developers understand the safety and efficacy of drug candidates. As a preclinical ophthalmology CRO, Ace Therapeutics provides a complete set of ADME detection and analysis services to support early ADME research of ophthalmic small molecule compounds, thereby increasing the possibility of project success sex. Our innovative ADME solution identifies exogenous and endogenous metabolites in all ocular tissues.
ADME (Absorption, Distribution, Metabolism and Excretion) properties are critical to understanding the safety and efficacy of a drug candidate, thereby increasing the likelihood of project success. The DMPK (Drug Metabolism and Pharmacokinetics) properties of a product determine how much of the drug reaches the target area, and how long it remains there.
As a preclinical CRO in ophthalmology, Ace Therapeutics supports all standard DMPK assays for the analysis of candidate compounds and generates custom assays to meet your project needs. Benefit from our state-of-the-art technology and experienced DMPK team. We conduct early in vitro and in vivo ADME studies for the development of ophthalmic small molecule compounds for global clients. These support the selection of compounds with the best ADME properties as drug candidates for further development.
ADME test results can be used to predict how they will behave in the body and to assess their potential for adverse interactions with other drugs. Our medicinal chemists use this valuable information, combined with biological screening data, to select compounds for investigation and identify drug candidates in the shortest possible time. At Ace Therapeutics, our innovative ADME solution identifies exogenous and endogenous metabolites in all biological samples and identifies biomarkers using targeted or untargeted assays.
Our world-class expertise in the qualitative and quantitative analysis of small molecules, peptides and proteins in tears and ocular tissue minimizes human error and provides highly reproducible and accurate data to help meet The tight timelines required for drug discovery.
As part of early ADME studies, Ace Therapeutics can microdissect and sample each ocular structure, including:
Ace Therapeutics has many years of combined industry experience in small molecule drug discovery. With professional knowledge in ADME and ophthalmology, our expert team is committed to providing high-quality early ADME research services to global customers to find lead compounds quickly and efficiently. If you are interested in our services or need more detailed information, please feel free to contact us. Our experienced scientists are ready to help you!